170 related articles for article (PubMed ID: 27058664)
1. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L; Gambino V; Raaijmakers J; Schlicker A; Fumagalli A; Russo M; Villanueva A; Beerling E; Bartolini A; Mollevi DG; El-Murr N; Chiron M; Calvet L; Nicolazzi C; Combeau C; Henry C; Simon IM; Tian S; in 't Veld S; D'ario G; Mainardi S; Beijersbergen RL; Lieftink C; Linn S; Rumpf-Kienzl C; Delorenzi M; Wessels L; Salazar R; Di Nicolantonio F; Bardelli A; van Rheenen J; Medema RH; Tejpar S; Bernards R
Cell; 2016 Apr; 165(2):317-30. PubMed ID: 27058664
[TBL] [Abstract][Full Text] [Related]
2. Linking Nucleoporins, Mitosis, and Colon Cancer.
Wong RW; D'Angelo M
Cell Chem Biol; 2016 May; 23(5):537-539. PubMed ID: 27203373
[TBL] [Abstract][Full Text] [Related]
3. The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.
Klotz DM; Nelson SA; Kroboth K; Newton IP; Radulescu S; Ridgway RA; Sansom OJ; Appleton PL; Näthke IS
J Cell Sci; 2012 Feb; 125(Pt 4):887-95. PubMed ID: 22399804
[TBL] [Abstract][Full Text] [Related]
4. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
5. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
6. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine in cancer therapy.
Capasso A
Curr Drug Targets; 2012 Jul; 13(8):1065-71. PubMed ID: 22594474
[TBL] [Abstract][Full Text] [Related]
8. Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast.
Carassai P; Jocollé G; Donati G; Spinazzé S; Baiocco C; Baderna P; Martinet A; Lococo F; Migliaccio F; Rossi G
Pathologica; 2017 Dec; 109(4):426-428. PubMed ID: 29449740
[No Abstract] [Full Text] [Related]
9. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
[TBL] [Abstract][Full Text] [Related]
10. BRAF-Like Colorectal Cancer Cells Are Selectively Dependent on RANBP2.
Cancer Discov; 2016 Jun; 6(6):OF18. PubMed ID: 27102074
[TBL] [Abstract][Full Text] [Related]
11. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy.
Hastie R; Lim E; Sluka P; Campbell L; Horne AW; Ellett L; Hannan NJ; Brownfoot F; Kaitu'u-Lino TJ; Tong S
EBioMedicine; 2018 Mar; 29():166-176. PubMed ID: 29429891
[TBL] [Abstract][Full Text] [Related]
13. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.
Masuda A; Maeno K; Nakagawa T; Saito H; Takahashi T
Am J Pathol; 2003 Sep; 163(3):1109-16. PubMed ID: 12937152
[TBL] [Abstract][Full Text] [Related]
14. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
15. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
16. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
19. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
